Brief: Gracell Biotechnologies Doses First Patient In Phase 1B/2 Clinical Trial
26/09/2023 23:26
Sept 26 (Reuters) - Gracell Biotechnologies Inc
GRCL.O :
* GRACELL BIOTECHNOLOGIES DOSES FIRST PATIENT IN PHASE 1B/2
CLINICAL TRIAL IN U.S. EVALUATING GC012F FOR TREATMENT OF
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Source text for Eikon: ID:nGNXbPwL7V
Further company coverage: GRCL.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27